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Abstract 
Purpose: To evaluate the antitumor activity of doxorubicine (DOX)-loaded nanoemulsion (NE) on 
Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. 
Methods: The mice were divided into five groups (n = 20) according to the administered drug. Groups I 
- V were labeled as negative control (normal), positive control of the untreated EAC bearing mice (EAC 
control), blank nanoemulsion (BI-NE), DOX-loaded-NE (DOX/LNE) and free DOX (DOX-Sol), 
respectively. Cardiotoxicity was assessed by measuring changes in body and organ weight, analyzing 
serum enzymes and lipids, and examining histological changes in heart tissues by light microscopy. In 
addition, mean survival time (MST), increase in life span (ILS) and survival (S) of the mice were 
determined.  
Results: DOX/LNE group reduced levels of serum enzymes and lowered damage to heart tissues 
relative to DOX-Sol group. The MST of the DOX/LNE group (80 ± 0.0 days) was significantly greater 
than that for DOX-Sol group (34.6 ± 8.9 days), while ILS of DOX/LNE (265.30 days) was higher than 
that of DOX-Sol (57.99 days) by 4.6-fold.  
Conclusion: Administration of DOX/LNE to EAC-bearing mice improves the efficacy of DOX and 
reduce its side effects on the heart.  
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Cancer is a potential fatal disease, characterized 
by uncontrolled growth and spread of abnormal 
cells [1]. In spite of the spread of many 
anticancer drugs, there are still challenges in 
employing them in cancer therapy because of 
their poor bioavailability, water insolubility, high 
toxicity and nonspecific targeting which result in 
damaging the healthy cells. Doxorubicin (DOX) is 
one of the most effective anticancer drugs, with a 
wide scope of activity in human cancers, 
including acute lymphoblastic leukemia, breast 
carcinoma, ovarian carcinoma, and 
hepatocellular carcinoma [2]. However, its clinical 
application is limited by its harmful side effects, 
the most significant of which is its cardiotoxicity 
that can lead to cardiomyopathy and congestive 
heart failure [3]. 
 
A variety of approaches have been reported to 
minimize the effective chemotherapeutic dose 
and thereby its side effects. It is possible to 
devise nanocarriers to deliver anticancer drugs 
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which would allow efficient passage and high 
bioavailability of the anticancer drugs. 
Nanoemulsions (NE) are one of the promising 
nanocarriers for many drugs [4]. They are non-
equilibrium, heterogeneous systems consisting of 
two immiscible liquids and mixed surfactants and 
cosurfactants which facilitate the dispersion of 
one liquid in the other as droplets with diameters 
ranging from 1 to 100 nm [5]. Anticancer drugs 
loaded in NE systems have greater activity 
against cancer cells in comparison to other 
emulsification systems. This is due to the 
decreased particle size and zeta potential, 
production of a stable water dispersion, reduced 
polydispersity index, and greater stability of drug 
with the NE [6].  
 
In the current study, the anticancer activity of the 







DOX hydrochloride was obtained from 
Pharmacopeia, California, US. Soya 
phosphatidylcholine (SPC), sodium oleate (SO), 
tris (hydroxymethyl) amino methane, 
polyoxyethyleneglycerol trihydroxystearate 40 
(Eumulgin HRE 40, EU) and hydrochloric acid 
(HCl) were purchased from Leo Chem., S. 
Puran, Bangalore, India. Cholesterol (CHO) was 
purchased from Jechno pharmacies 
BanadurGarh, Haryana, India. 1-Octanol was 
obtained from AflaAesar GmbH & Co KG 




Healthy female Swiss albino mice weighing 25 – 
30 g were used for the experiment. The animals 
were housed in large polypropylene cages with 
utmost of five animals per cage and maintained 
under standard laboratory conditions 
(temperature 25 ± 2 °C with dark/light cycle 
12/12 h) and provided with standardized pelleted 
feed and clean drinking water ad libitum. The 
animals were maintained in accordance with 
King Abdulaziz University's policy and 
international guidelines on the care and use of 
laboratory animals [7]. Ethical approval was 
obtained from Research Ethics Committee of 
Faculty of Medicine at King Abdulaziz University 
(approval ref. no. 189/247/1433). Ehrlich ascites 
carcinoma (EAC) cells were obtained from 
American Type Tissue Culture Collection 
(Manassas, VA, USA). 
 
Preparation of nanoemulsion formulations 
 
The nanoemulsion (NE) formulation was 
prepared as described elsewhere [8]. In brief, a 
1.25 % (wt/wt) of the solid surfactants, 
EU/SPC/SO, were mixed at fixed ratio of 
3.5:3.0:3.5. Then, a 0.125 % (wt/wt) of the oil 
phase of CHO was added slowly to the 
surfactant mixture until a semisolid phase was 
formed. After that, a 1 % (wt/wt) of 1-octanol was 
added dropwise. Finally, the mixture was diluted 
with the aqueous phase of 97.63 % (wt/wt) of 
warm Tris–HCl buffer (pH 7.22). The mixture was 
kept in the water bath at 75 °C for three hours to 
be clear and transparent and the resulted NE 
formula was stored at 25 °C. The NE formulas 
were BI-NE, DOX/LNE, prepared by solubilizing 
2.0 mg of DOX/ kg of mice in 0.2 ml of NE. The 
DOX-Solution (DOX-Sol) was prepared by 
dissolving 2.0 mg of DOX in 0.2 ml of distilled 
water. 
 
In vivo antitumor activity 
 
Transplantation of tumor and experimental 
protocol 
 
The in vivo evaluation of the antitumor activity of 
different drug formulations was performed by 
using the regimen of Alkreathy et al [9]. The EAC 
cells were maintained in the ascitic form by 
sequential passages in the mice, by means of 
intraperitoneal (i.p.) transplantation of 2.5 × 106 
cells/mouse every 10 days. Ascitic fluid was 
drawn out from EAC bearing mice at the 8th day 
following transplantation. Before injection, the 
viable EAC cells, collected from the peritoneal 
cavity, were counted by trypan blue exclusion 
test. 
 
The mice were divided into five groups (n = 20) 
according to the administered drug, at which 
Group I-V were labeled as negative control 
(normal), positive control of the untreated EAC 
bearing mice (EAC control), BI-NE, DOX/LNE 
and DOX-Sol, respectively. The body weight of 
all mice was taken before injection with EAC cell. 
All of the mice in each group were injected i.p. 
with 2.5 × 106 EAC cells/mouse at day zero, 
except group I which was injected with saline 
solution. After 24 h, animals in Groups III-V were 
injected with 3 doses of the desired drug, every 
other day. 
 
On the 15th day, ten mice from each group were 
fasted for 24 h and the body weight of each 
mouse was taken on a digital scale. Then, the 
blood was collected by a retro orbital plexus 
method for the estimation of serum biochemical 
assays. Finally, these animals were sacrificed for 
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histology investigation. The rest of the animals in 
each group were kept for the survival study. 
 
Relative organ weight 
 
Immediately following sacrifice, the hearts of all 
of the mice were removed, washed with buffer 
and dried on blotting paper. Then all hearts were 
weighed on a digital scale. To compute the organ 
weight-to-body weight ratio, the post-sacrifice 
organs (heart) weight (B) from the same animal 
was divided by the pre-sacrifice body weight for 
each animal (A).  
 
Determination of biochemical parameters 
 
For biochemical assays, the blood samples were 
allowed to clot and the serum was separated by 
centrifugation at 5000 RPM for 10 min. Serum 
was utilized for the estimation of cardiac 
enzymes (creatine phosphokinase (CK) and 
lactate dehydrogenase (LDH)) and the serum 
lipid profile (cholesterol (CHO), high density 
lipoprotein (HDL) and triglyceride (TG)). The 
biochemical assays were performed according to 
the standard kit methods using fully Automated 
COBAS® 8000 modular analyzer series in the 
King Fahd Armed Forces Hospital–Jeddah, 




The collected heart tissues were fixed in 10 % 
neutral buffered formalin (4 % formaldehyde in 
phosphate buffered saline). Thereafter, the 
tissues were incrementally dehydrated by 
increasing concentrations of alcohol and then 
stained with hematoxylin and eosin (H & E), 




The observation period of the survival study 
began in the first weeks of age until the study 
ended at the twelfth week of age. The MST, % 
ILS and % S of each group containing ten mice 
were monitored by recording the daily mortality 
for 80 days. ILS were calculated using Eq 1 [10]. 
 
ILS (%) = {(St/Sc) – 1}100 …………………. (1) 
 
where St and Sc are the mean survival time of 




All values were expressed as mean ± standard 
deviation (SD; n = 10). Statistical analysis was 
performed with one-way analysis of variance 
(ANOVA) test and independent sample t-test 
using MegaStat Excel (version 10.3, Butler 
University). The significant differences between 
the tested samples were classified according to 
the p-value. If p < 0.001, the difference was 
considered very highly significant (***); p < 0.01 
was considered highly significant (**); the 





Body weight change and relative organ 
weight  
 
As displayed in Figure 1A, there was a very high 
significant increase in the body weight changes 
of EAC control  and BI-NE groups compared with 
the normal group (P-value < 0.001) whereas the 
enhancement in the body weight change was 
reduced in the DOX/LNE group (p < 0.05). On 
the other hand, there was a significant decrease 
in the body weight change in the DOX–Sol group 
(p < 0.05). Studying the effect of the drug 
formulations on the heart weight relative to the 
body weight revealed that the mice treated with 
DOX–Sol, DOX/LNE and BI-NE showed no 
significant difference from the normal group in 
heart-to-body weight ratio, whereas EAC control 
group showed a significant decrease in the heart-
to-body weight ratio (Figure 1B). 
 
Cardiac enzymes and lipid profile 
 
The effect of the drug formulations on the heart 
enzymes and lipid profile is exhibited in Table 1. 
The CK levels in the EAC control and BI-NE 
groups were comparable with the normal group. 
In spite of the significant increase in the CK 
levels in both of DOX–Sol and DOX/LNE relative 
to the normal group, the CK level of DOX/LNE 
group was significantly less than DOX–Sol 
group. Nevertheless, the CK levels in all of the 
groups were within the standard range of the 
enzyme in the mice (50-680 IU/l). Furthermore, 
all treated groups showed a significant increase 
in the LDH levels when compared to the normal 
group. However, the increase in the LDH levels 
in all of the groups were within the standard 
range of the albino mice, which is (85-750 IU/l), 
except DOX–Sol group which had elevated 
levels of LDH. 
 
Regarding the lipid profile, there were no 
significant changes in CHO level between the 
normal group and the other treated groups 
except DOX–Sol group which had reduced 
amount of CHO. On the other hand, all treated 
groups did not show any considerable difference 
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Figure 1: The effect of the drug formulations on the A) body weight change and B) heart-to-body weight ratio of 
EAC bearing mice. The significant differences between the treated and the normal groups were classified 
statistically according to the p-value. If the p < 0.001, the difference was considered very highly significant (***) 
while if 0.001 < p < 0.01 was considered highly significant (**). If the p < 0.05, the difference was considered 
significant (*) 
 
Table 1: Effect of drug formulations on the cardiac enzymes and lipid profile in EAC-bearing mice 
 
Group CK LDH CHO HDL TG 
Normal 136.63±89.28 163.80±145.85 28.00±3.44 21.03±6.21 12.80±0.62 
EAC Control 206.88±76.33 589.66±42.71** 24.70±4.52 14.00±2.52 18.23±9.44 
BI-NE 182.33±114.94 758.33±79.09*** 28.77±3.41 17.33±4.85 16.00±6.94 
DOX/LNE 423.44±7.12** 594.66±303.00** 32.30±1.60 24.95±3.55 15.65±3.85 
DOX–Sol 603.66±21.68*** 1074.44±36.71*** 18.00±1.00** 15.47±0.45 5.90±0.30 
Significant differences between the treated and the normal groups were classified statistically according to the p-
value. If p < 0.001, the difference was considered very highly significant (***) while if 0.001< p < 0.01 was 
considered highly significant (**). If p < 0.05, the difference was considered significant (*) 
 





The histopathological examination of the heart 
tissues of mice in the EAC control group showed 
normal architectures as no inflammatory cell 
infiltration was seen (Figure 2A). The tissue of 
the mice treated with BI-NE showed normal 
myocardium morphology almost similar to the 
EAC control group except some nuclei have 
endured karyolysis, which is known as the 
complete dissolution of the chromatin of a dying 
cell due to enzymatic degradation by 
endonucleases, while others were pyknotic, 
which is the irreversible condensation of 
chromatin in the nucleus of a cell undergoing 
necrosis or apoptosis followed by fragmentation 
of the nucleus (Figure 2B). Mice treated with 
DOX-Sol showed damages in the heart tissues, 
including the loss of myofibrils (myofibrillar 
fragmentation), congestion of blood vessels, a 
stimulation of cytoplasmic vacuolization and 
some nuclei enduring karyolysis and pyknosis 
(Figure 2C). DOX-LNE group had a significant 
reduction in the severity of myocardial 
degeneration that was observed as mild 
disruption of cardiac muscle fibers and reduced 
cytoplasmic vacuolization (Figure 2D). 
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Figure 2: Photomicrographs of the myocardium of A) EAC control group, showing normal morphology B) BI-NE 
group, showing normal morphology almost similar to normal group except some cardiomyocytes endured 
karyolysis (K) while others were pyknotic (P), C) DOX–Sol group, showing damage in cardiomyscytes as 
indicated by increased cytoplasmic vacuolization (V), myofibrillar fragmentation (F) and congestion of blood 
vessels (B), and D) DOX/LNE group, revealing slight alteration in the morphology of the cardiomyocytes and 
considerably less cellular vacuolization and myofibrillar damage. H&E × 400 
 
Table 2: Effect of drug formulations on the MST, % ILS and % S. 
 
Group MST (days) ILS (%) S (%) 
Normal 80±0  100 
EAC Control 21.9±1.729*** ─ 0 
BI-NE 22.5±2.224*** 2.740 0 
DOX/LNE 80±0 265.297 100 
DOX–Sol. 34.6±8.877*** 57.991 0 
Significant differences between the treated and the normal groups were classified statistically according to the P-
value. If p < 0.001, the difference was considered very highly significant (***) while if 0.001<p < 0.01 was 




The effect of the drug formulations on the MST of 
EAC-bearing mice is illustrated in Table 2. 
Interestingly, the MST and % S of the DOX/LNE 
group was equivalent to the MST and % S of the 
normal group which was very highly significantly 
greater than the MST and % S of the EAC 
control, BI-NE and DOX-Sol groups. The % ILS 
of DOX/LNE was longer than the % ILS of DOX-
Sol by 4.6 folds. 
DISCUSSION 
 
The present study was carried out to evaluate 
the antitumor effect of the DOX-loaded-NE in one 
of the most devastating experimental tumor 
models, the EAC bearing mice. Because of their 
biocompatibility, NEs have been widely used in 
the medical field for delivery and controlled 
release of the hydrophobic anticancer drugs 
because they present a very large surface area 
and good long-term stability. As expected in the 
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EAC control group, a significant increase in body 
weight was observed [10]. However, animals 
treated with DOX–Sol showed a further 
significant decrease in the body weight indicating 
more reduction in the i.p. tumor burden. This 
result was similar to several studies which 
demonstrated that the use of DOX leads to a 
significant drop in the body weight of rats [11,12]. 
In 2013, Lv et al [13] proved that DOX loaded in 
nanoparticles exhibited higher antitumor efficacy 
on A549 lung-tumor-bearing mice compared with 
free DOX at the same dose. Moreover, from our 
experimental groups, we found that DOX/LNE 
group had a significant decrease in the body 
weight compared to the EAC control group.  
 
The reliable criterion for judging the value of any 
anticancer drug is the prolongation of life span of 
the tumor bearing animal [14]. The MST, % ILS 
and % S of EAC bearing mice treated with 
DOX/LNE were significantly longer than EAC 
bearing mice treated with DOX–Sol. This study is 
in agreement with Xiong et al [15] study, which 
showed that the life span of animals bearing 
MDA-435/LCC6WT (human breast cancer cell 
line) and treated with polymeric nanocarriers of 
DOX, was significantly longer than animals 
treated with free DOX. Additionally, Hao et al [16] 
demonstrated that nanoparticles can decrease 
the toxicity of DOX that result in a significant 
increase of the average lifetime in comparison 
with the free DOX.  
 
In the present work, heart weight-to-body weight 
ratios were assessed in order to evaluate the 
toxicity of the drug formulas on the whole organ. 
Mice treated with drug formulations that contain 2 
mg/ kg DOX did not show any significant change 
in heart weight-to-body weight ratio compared to 
the normal group. However, when rats were 
given three i.p injections of 5 mg/ kg DOX, a 
significant less mean ratio of heart weight to 
body weight against the control animals was 
reported [17]. 
 
DOX is a very potent antitumor antibiotic. Its use 
is severely limited for its cardiotoxicity, which 
have been documented in a variety of animal 
models [12]. During malignancy, the tumor 
marker enzymatic changes reflect overall 
changes in metabolism and they are increasingly 
appreciated as critical determinants of tumor cell 
behavior with sensitivity and specificity [18].  
 
The results of the present study indicate that 
mice treated with DOX-Sol had a significant 
increase in LDH and CK levels, important 
markers of cardiac injury, especially during 
clinical follow-up of DOX therapy. In agreement 
with our findings, Yagmurca et al [19] 
demonstrated similar elevations in cardiac 
enzymes activities in rats following challenge 
with a single cumulative dose of DOX. 
Generation of free radicals by DOX caused 
extensive damage in the myocardium, which 
result in increased membrane permeability and 
hence leads to leakage of LDH and CK enzymes. 
On the other hand, administering DOX/LNE into 
the EAC bearing mice reduced the enhancement 
in the cardiac enzymes relative to the DOX-Sol. 
Park et al [20] proved that DOX-loaded-
nanoparticle decreased the observed cardiac 
toxicity by decreasing CK level compared to the 
DOX treated group.  
 
In the present study, it has been found that mice 
treated with Dox-Sol had significantly decreased 
levels in CHO compared to normal group. The 
levels of TG and HDL in mice were not affected 
by the different treated drug formulas. In 
contrast, rat treated with DOX at a total 
cumulative dose of 15 mg/kg through i.p showed 
that DOX interferes with metabolism and 
biosynthesis of lipids led to significantly 
increased levels of TG, CHO and decreased 
level of HDL [21]. 
 
According to the light microscopy images in the 
present study, heart sections of mice treated with 
DOX-Sol showed massive pathological changes 
compared to the normal architecture observed in 
the EAC control group. As observed in the heart 
tissue, the damages induced by DOX-Sol include 
the loss of myofibrils, congestion of blood 
vessels, stimulation in the cytoplasmic 
vacuolization and some nuclei enduring 
karyolysis and pyknosis. The histopathological 
changes observed in the DOX-Sol group were 
similar to those previously reported [22-24].  As 
noted from the histological reports, the heart 
myocytes degeneration could have resulted in 
the leakage of enzymes into the blood stream. 
Unlike DOX-Sol group, the heart tissue of 
DOX/LNE group was similar to the EAC control 
group sections in showing a normal tissue 
architecture. This result indicated that loading 
DOX in NE formulation reduced the damages 




The main goal of the current study was to assess 
the anticancer activity of DOX-loaded NE in vivo. 
Loading DOX into NE considerably improves its 
efficacy while reducing its cardiotoxicity. These 
findings suggest that NE is a promising 
nanocarrier for DOX. However, studies using 
other animals are required to confirm these 
findings and evaluate the possible toxicological 
effects of this new formulation in human patients. 
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